Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Active site-based analysis of structural proteins for drug targets in different human Coronaviruses

K. Ahmadi, F. Zahedifard, L. Mafakher, M. Ali Einakian, T. Ghaedi, S. Kavousipour, S. Faezi, A. Karmostaji, K. Sharifi-Sarasiabi, H. Gouklani, M. Hassaniazad

. 2022 ; 99 (4) : 585-602. [pub] 20220201

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc22018920

Grant support
Hormozgan University of Medical Sciences

Seven types of Coronaviruses (CoVs) have been identified that can cause infection in humans, including HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, SARS-CoV, HCoV-MERS, and SARS-CoV-2. In this study, we investigated the genetic structure, the homology of the structural protein sequences, as well as the investigation of the active site of structural proteins. The active site of structural proteins was determined based on the previous studies, and the homology of their amino acid sequences and structure was compared. Multiple sequence alignment of Spike protein of HCoVs showed that the receptor-binding domain of SARS-CoV-2, SARS-CoV, and MERS-CoV was located at a similar site to the S1 subunit. The binding motif of PDZ (postsynaptic density-95/disks large/zona occludens-1) of the envelope protein, was conserved in SARS-CoV and SARS-CoV-2 according to multiple sequence alignment but showed different changes in the other HCoVs. Overall, spike protein showed the most variation in its active sites, but the other structural proteins were highly conserved. In this study, for the first time, the active site of all structural proteins of HCoVs as a drug target was investigated. The binding site of these proteins can be suitable targets for drugs or vaccines among HCoVs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018920
003      
CZ-PrNML
005      
20220804135203.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/cbdd.14004 $2 doi
035    __
$a (PubMed)34914204
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ahmadi, Khadijeh $u Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
245    10
$a Active site-based analysis of structural proteins for drug targets in different human Coronaviruses / $c K. Ahmadi, F. Zahedifard, L. Mafakher, M. Ali Einakian, T. Ghaedi, S. Kavousipour, S. Faezi, A. Karmostaji, K. Sharifi-Sarasiabi, H. Gouklani, M. Hassaniazad
520    9_
$a Seven types of Coronaviruses (CoVs) have been identified that can cause infection in humans, including HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, SARS-CoV, HCoV-MERS, and SARS-CoV-2. In this study, we investigated the genetic structure, the homology of the structural protein sequences, as well as the investigation of the active site of structural proteins. The active site of structural proteins was determined based on the previous studies, and the homology of their amino acid sequences and structure was compared. Multiple sequence alignment of Spike protein of HCoVs showed that the receptor-binding domain of SARS-CoV-2, SARS-CoV, and MERS-CoV was located at a similar site to the S1 subunit. The binding motif of PDZ (postsynaptic density-95/disks large/zona occludens-1) of the envelope protein, was conserved in SARS-CoV and SARS-CoV-2 according to multiple sequence alignment but showed different changes in the other HCoVs. Overall, spike protein showed the most variation in its active sites, but the other structural proteins were highly conserved. In this study, for the first time, the active site of all structural proteins of HCoVs as a drug target was investigated. The binding site of these proteins can be suitable targets for drugs or vaccines among HCoVs.
650    _2
$a katalytická doména $7 D020134
650    12
$a Coronavirus $x chemie $7 D017934
650    _2
$a lidé $7 D006801
650    12
$a virus SARS $x chemie $7 D045473
650    12
$a SARS-CoV-2 $x chemie $7 D000086402
650    12
$a glykoprotein S, koronavirus $x chemie $7 D064370
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Zahedifard, Farnaz $u Drug Discovery and Evaluation Unit, Department of Parasitology, Biocev, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Mafakher, Ladan $u Medicinal Plant Research Center, Ahvaz Jundishapur of Medical Science, Ahvaz, Iran
700    1_
$a Ali Einakian, Mohammad $u Food Health Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
700    1_
$a Ghaedi, Tayebeh $u Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
700    1_
$a Kavousipour, Soudabeh $u Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
700    1_
$a Faezi, Sobhan $u Department of Microbiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran $u Medical Biotechnology Research Center, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran
700    1_
$a Karmostaji, Afsaneh $u Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
700    1_
$a Sharifi-Sarasiabi, Khojasteh $u Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
700    1_
$a Gouklani, Hamed $u Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
700    1_
$a Hassaniazad, Mehdi $u Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
773    0_
$w MED00173265 $t Chemical biology & drug design $x 1747-0285 $g Roč. 99, č. 4 (2022), s. 585-602
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34914204 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135157 $b ABA008
999    __
$a ok $b bmc $g 1822490 $s 1170163
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 99 $c 4 $d 585-602 $e 20220201 $i 1747-0285 $m Chemical biology & drug design $n Chem Biol Drug Des $x MED00173265
GRA    __
$p Hormozgan University of Medical Sciences
LZP    __
$a Pubmed-20220720
Back

Find record

Citation metrics

Archiving options